Exicure Inc. (XCUR): Market Cap to Revenue Ratio

Brandmark of Exicure Corp (XCUR)

Exicure, Inc. (XCUR) adheres to basic environmental standards, minimizing environmental impact within its laboratories. Management is currently restructuring the business in an effort to preserve intellectual capital for survival. The current P/S ratio reflects the price-to-sales valuation trend, where the metric is fixed at 70.90. Transitioning to a patent licensing model reduces R&D costs, establishing a foundation for stable cash flow.

XCUR Exicure Corp: Market Cap to Revenue in the range 07/04/2022 - 06/28/2025

Analytical breakdowns for Exicure, Inc. (XCUR)

- price and consensus price forecast:
- stock exchange capitalization data:
Summary company analytics:XCUR Exicure Inc.
Manufactured products of Exicure

The P/S multiple determines the market value of each unit of generated revenue, reflecting the business valuation relative to its sales. By analyzing the average P/S of a company, an investor can observe capitalization dynamics linked to actual cash flow. High sensitivity of this indicator to price fluctuations signals a speculative nature of the valuation. For Exicure, Inc. (XCUR), this is critical, as asset restructuring and liquidity shortages amplify the volatility of this metric.

Competitors of Exicure, Inc.

Price-to-Revenue Coefficient Tempus AI|Price-to-Revenue Ratio Qiagen QGEN|IONS: Market Cap to Revenue Ratio|Repligen Corp. - P/S Multiple|Avidity Corp (RNA) - Market Cap to Revenue|CRSP (CRISPR Therapeutics AG) - Market Cap to Revenue|WGS - Price-to-Revenue Coefficient|Market Cap to Revenue RARE|Market Cap to Revenue Ratio BEAM (Beam Therapeutics Inc)|P/S Multiple SRPT|Market Cap to Revenue Twist Bioscience Corp TWST|10x Genomics, Inc. - Market Cap to Revenue|P/S Multiple intelliatx.com NTLA|STOK - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio BLFS (BioLife Solutions Inc)|WVE: P/S Multiple|Market Cap to Revenue Ratio MAZE|Price-to-Revenue Ratio Sionna Therapeutics Inc|Market Cap to Revenue Ratio PRME (primemedicine.com)|P/S Multiple TSHA|P/S Multiple uniQure NV (QURE)|P/S Multiple MGTX (MeiraGTx PLC)|REGENXBIO Corp (RGNX) - Price to Sales|SLDB: Market Cap to Revenue|OCGN (ocugen.com) - Market Cap to Revenue Ratio|PACB: P/S Multiple|BNTC - Price-to-Revenue Coefficient|DSGN (Design Pharma) - P/S Multiple|Market Cap to Revenue Rocket Corp (RCKT)|Market Cap to Revenue FDMT (4D Molecular Therapeutics)|P/S Multiple lexeotx.com (LXEO)|Price-to-Revenue Ratio Korro Bio KRRO|Market Capitalization-to-Revenue Ratio EDIT|Silence Therapeutics Inc. - P/S Multiple|Price to Sales ProQR Therapeutics N.V.|CDXS (codexis.com) - Market Cap to Revenue|sangamo.com - Market Capitalization-to-Revenue Ratio|NAUT (Nautilus Biotechnology, Inc.) - P/S Multiple|Metagenomi Inc. (MGX) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Precision BioSciences, Inc. (DTIL)|generationbio.com - Market Cap to Revenue Ratio|P/S Multiple BOLD (Boundless Bio, Inc.)|IMNN - Market Cap to Revenue|PHIO: Market Cap to Revenue|Price-to-Revenue Coefficient Mustang Bio, Inc. MBIO|RNAZ (transcodetherapeutics.com) - Market Cap to Revenue|Market Cap to Revenue Ratio BNGO|APDN (Applied DNA Sciences) - P/S Multiple|Market Cap to Revenue bluebirdbio.com (BLUE)|Market Cap to Revenue IPA (ImmunoPrecise Antibodies)|P/S Multiple Omega Therapeutics Inc (OMGA)|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|Market Capitalization-to-Revenue Ratio RGLS|Syros Pharmaceuticals - P/S Multiple|TBIO (telesisbio.com) - Market Cap to Revenue Ratio|TRACON Pharmaceuticals, Inc. (TCON) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio UBX